STRIDES PHARMA SCIENCE | SHASUN PHARMA | STRIDES PHARMA SCIENCE/ SHASUN PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 47.9 | 123.9 | 38.7% | View Chart |
P/BV | x | 2.2 | 8.5 | 26.2% | View Chart |
Dividend Yield | % | 0.2 | 0.2 | 93.1% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
STRIDES PHARMA SCIENCE Mar-18 |
SHASUN PHARMA Mar-14 |
STRIDES PHARMA SCIENCE/ SHASUN PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,147 | 94 | 1,217.6% | |
Low | Rs | 642 | 46 | 1,407.9% | |
Sales per share (Unadj.) | Rs | 317.2 | 214.2 | 148.1% | |
Earnings per share (Unadj.) | Rs | 7.8 | 5.3 | 147.0% | |
Cash flow per share (Unadj.) | Rs | 25.1 | 15.8 | 158.4% | |
Dividends per share (Unadj.) | Rs | 2.00 | 1.00 | 200.0% | |
Dividend yield (eoy) | % | 0.2 | 1.4 | 15.6% | |
Book value per share (Unadj.) | Rs | 274.3 | 53.3 | 514.1% | |
Shares outstanding (eoy) | m | 89.50 | 56.62 | 158.1% | |
Bonus/Rights/Conversions | ESOP | - | - | ||
Price / Sales ratio | x | 2.8 | 0.3 | 863.9% | |
Avg P/E ratio | x | 114.0 | 13.1 | 870.4% | |
P/CF ratio (eoy) | x | 35.7 | 4.4 | 808.0% | |
Price / Book Value ratio | x | 3.3 | 1.3 | 248.9% | |
Dividend payout | % | 25.5 | 18.7 | 136.0% | |
Avg Mkt Cap | Rs m | 80,058 | 3,958 | 2,022.8% | |
No. of employees | `000 | 2.5 | NA | - | |
Total wages/salary | Rs m | 4,341 | 2,164 | 200.6% | |
Avg. sales/employee | Rs Th | 11,325.8 | NM | - | |
Avg. wages/employee | Rs Th | 1,731.4 | NM | - | |
Avg. net profit/employee | Rs Th | 280.1 | NM | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 28,394 | 12,127 | 234.1% | |
Other income | Rs m | 941 | 229 | 410.1% | |
Total revenues | Rs m | 29,334 | 12,356 | 237.4% | |
Gross profit | Rs m | 3,965 | 1,009 | 393.0% | |
Depreciation | Rs m | 1,540 | 594 | 259.5% | |
Interest | Rs m | 1,962 | 415 | 472.8% | |
Profit before tax | Rs m | 1,403 | 230 | 610.9% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | -168 | 0 | 56,000.0% | |
Extraordinary Inc (Exp) | Rs m | -436 | 0 | - | |
Tax | Rs m | 97 | -73 | -133.8% | |
Profit after tax | Rs m | 702 | 302 | 232.4% | |
Gross profit margin | % | 14.0 | 8.3 | 167.8% | |
Effective tax rate | % | 6.9 | -31.7 | -21.9% | |
Net profit margin | % | 2.5 | 2.5 | 99.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 24,836 | 6,884 | 360.8% | |
Current liabilities | Rs m | 18,993 | 8,456 | 224.6% | |
Net working cap to sales | % | 20.6 | -13.0 | -158.8% | |
Current ratio | x | 1.3 | 0.8 | 160.6% | |
Inventory Days | Days | 71 | 62 | 115.2% | |
Debtors Days | Days | 113 | 108 | 105.4% | |
Net fixed assets | Rs m | 34,289 | 4,970 | 689.9% | |
Share capital | Rs m | 895 | 113 | 789.9% | |
"Free" reserves | Rs m | 23,651 | 2,875 | 822.7% | |
Net worth | Rs m | 24,546 | 3,020 | 812.7% | |
Long term debt | Rs m | 15,513 | 1,817 | 853.6% | |
Total assets | Rs m | 65,437 | 13,347 | 490.3% | |
Interest coverage | x | 1.7 | 1.6 | 110.4% | |
Debt to equity ratio | x | 0.6 | 0.6 | 105.0% | |
Sales to assets ratio | x | 0.4 | 0.9 | 47.8% | |
Return on assets | % | 4.1 | 5.4 | 75.8% | |
Return on equity | % | 2.9 | 10.0 | 28.6% | |
Return on capital | % | 6.9 | 13.3 | 51.7% | |
Exports to sales | % | 0 | 46.4 | 0.0% | |
Imports to sales | % | 0 | 14.2 | 0.0% | |
Exports (fob) | Rs m | NA | 5,622 | 0.0% | |
Imports (cif) | Rs m | NA | 1,728 | 0.0% | |
Fx inflow | Rs m | 15,697 | 5,843 | 268.7% | |
Fx outflow | Rs m | 735 | 2,173 | 33.8% | |
Net fx | Rs m | 14,962 | 3,669 | 407.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,871 | 398 | 470.5% | |
From Investments | Rs m | 5,826 | -1,635 | -356.3% | |
From Financial Activity | Rs m | -10,157 | 1,309 | -776.2% | |
Net Cashflow | Rs m | -2,615 | 71 | -3,672.6% |
Indian Promoters | % | 27.7 | 39.2 | 70.7% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 37.8 | 3.6 | 1,050.0% | |
FIIs | % | 8.6 | 17.6 | 48.9% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 25.9 | 39.6 | 65.4% | |
Shareholders | 56,241 | 20,750 | 271.0% | ||
Pledged promoter(s) holding | % | 0.0 | 12.3 | - |
Compare STRIDES PHARMA SCIENCE With: NEULAND LABS WYETH ABBOTT INDIA ALEMBIC DR. REDDYS LAB
Compare STRIDES PHARMA SCIENCE With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
This could take India to the position of 3rd largest economy.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
This ignored sector could deliver big short-term profits.
More